Executive search firm Toft Group has placed Bill Williams, PhD as Senior Vice President, Commercial Operations for Novoheart (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company.
Dr. Williams has over 20 years of experience in the life science industry spanning business development, sales and marketing. He was most recently Vice President, Global Sales, Marketing and Business Development with Organovo, Inc. He joined Organovo from Aushon Biosystems where he spent 3 years as their Vice President, Global Sales and Marketing. Earlier in his industry career, Dr. Williams held management roles for Ciphergen Biosystems and Beckman Coulter.
Dr. Williams holds a PhD in Analytical Chemistry from Texas A&M University.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as ‘human heart-in-a-jar’, Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.